(Inebilizumab)Biosimilar Reference Antibody-GS40337

货号：GS40337

Inebilizumab (brand name Uplizna®) is a humanized monoclonal IgG1κ antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive. It functions as a B-cell depleting therapy by targeting CD19, a cell surface antigen. By binding to CD19 with high affinity, inebilizumab induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the rapid and sustained depletion of a broad range of B-lineage cells, including pre-B cells, mature B cells, and some plasma blasts. This depletion is believed to reduce the production of pathogenic autoantibodies (like anti-AQP4 IgG) and modulate the inflammatory environment that drives NMOSD attacks.